Roles of A20 in autoimmune diseases

[1]  Dongmei Zhang,et al.  Decreased A20 mRNA and protein expression in peripheral blood mononuclear cells in patients with type 2 diabetes and latent autoimmune diabetes in adults. , 2014, Diabetes research and clinical practice.

[2]  P. Gaffney,et al.  An Enhancer Element Harboring Variants Associated with Systemic Lupus Erythematosus Engages the TNFAIP3 Promoter to Influence A20 Expression , 2013, PLoS genetics.

[3]  Bangxing Hong,et al.  A20 Controls Macrophage to Elicit Potent Cytotoxic CD4+ T Cell Response , 2012, PloS one.

[4]  Yu-Chen Fan,et al.  Down-Regulation of A20 mRNA Expression in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus , 2012, Journal of Clinical Immunology.

[5]  S. Damrauer,et al.  A20-Mediated Modulation of Inflammatory and Immune Responses in Aortic Allografts and Development of Transplant Arteriosclerosis , 2012, Transplantation.

[6]  H. Yoshikawa,et al.  A pro-inflammatory role for A20 and ABIN family proteins in human fibroblast-like synoviocytes in rheumatoid arthritis. , 2012, Immunology letters.

[7]  N. Rose,et al.  Faculty Opinions recommendation of Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. , 2012 .

[8]  M. Kool,et al.  A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis , 2011, Nature Genetics.

[9]  Takashi Nakamura,et al.  A20 silencing by lipid envelope-type nanoparticles enhances the efficiency of lipopolysaccharide-activated dendritic cells. , 2011, Biological & pharmaceutical bulletin.

[10]  H. Hammad,et al.  The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. , 2011, Immunity.

[11]  G. Ingravallo,et al.  A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren’s syndrome , 2011, Histochemistry and Cell Biology.

[12]  P. Rosenstiel,et al.  Genome-Wide Expression Profiling Identifies an Impairment of Negative Feedback Signals in the Crohn’s Disease-Associated NOD2 Variant L1007fsinsC , 2011, The Journal of Immunology.

[13]  A. Waisman,et al.  A20 deficiency in B cells enhances B‐cell proliferation and results in the development of autoantibodies , 2011, European journal of immunology.

[14]  P. Gregersen,et al.  Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus , 2011, Nature Genetics.

[15]  K. Amann,et al.  B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. , 2011, Blood.

[16]  D. Ray,et al.  Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. , 2010, Clinical and experimental rheumatology.

[17]  C. Liu,et al.  The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. , 2010, Immunity.

[18]  Byung-Hyun Park,et al.  A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. , 2010, Arthritis and rheumatism.

[19]  M. Pasparakis,et al.  Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor–induced toxicity and experimental colitis , 2010, The Journal of experimental medicine.

[20]  G. van Loo,et al.  The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. , 2009, Trends in immunology.

[21]  P. Marynen,et al.  A20 Negatively Regulates T Cell Receptor Signaling to NF-κB by Cleaving Malt1 Ubiquitin Chains1 , 2009, The Journal of Immunology.

[22]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[23]  P. Gaffney,et al.  Meta-analysis and Imputation Identifies a 109 kb Risk Haplotype Spanning TNFAIP3 Associated with Lupus Nephritis and Hematologic Manifestations , 2009, Genes and Immunity.

[24]  R. Beyaert,et al.  A20: Central Gatekeeper in Inflammation and Immunity* , 2009, Journal of Biological Chemistry.

[25]  J. Aerts,et al.  Attenuated Expression of A20 Markedly Increases the Efficacy of Double-Stranded RNA-Activated Dendritic Cells As an Anti-Cancer Vaccine1 , 2009, The Journal of Immunology.

[26]  R. Arsenescu,et al.  Signature biomarkers in Crohn's disease: toward a molecular classification , 2008, Mucosal Immunology.

[27]  Pui-Yan Kwok,et al.  Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus , 2008, Nature Genetics.

[28]  D. Philpott,et al.  The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. , 2008, Immunity.

[29]  L. Rollins,et al.  A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell–mediated suppression , 2008, Nature Medicine.

[30]  Georg Schett,et al.  Cytokines in the pathogenesis of rheumatoid arthritis , 2007, Nature Reviews Immunology.

[31]  Yi Sun,et al.  SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation. , 2007, Cancer research.

[32]  S. Grey,et al.  Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection. , 2006, Diabetes.

[33]  Matthew T Wheeler,et al.  The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses , 2004, Nature Immunology.

[34]  D. Wallach.  Faculty Opinions recommendation of De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. , 2004 .

[35]  G Cantarella,et al.  Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. , 2000, Immunity.

[36]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[37]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[38]  D. Figeys,et al.  The proteomic reactor facilitates the analysis of affinity-purified proteins by mass spectrometry: application for identifying ubiquitinated proteins in human cells. , 2007, Journal of proteome research.

[39]  K. Rajewsky,et al.  B cell recruitment and selection in mouse GALT germinal centers. , 2006, Current topics in microbiology and immunology.

[40]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.